Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Qlt Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT

Completed

Conditions: Leber Congenital Amaurosis (LCA)
Retinitis Pigmentosa (RP)

First Posted Date: 2015-10-14

Last Posted Date: 2016-04-29

Lead Sponsor: QLT Inc.

Target Recruit Count: 59

Registration Number: NCT02575430

Locations: 🇺🇸
Wilmer Eye Institute - Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Casey Eye Institute - Marquam Hill, Portland, Oregon, United States
🇨🇦
The Hospital for Sick Children, Ophthalmology and Vision Sciences, Toronto, Ontario, Canada

and more 6 locations

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

Phase 2

Completed

Conditions: Impaired Dark Adaptation

Interventions: Drug: QLT091001
Other: Placebo

First Posted Date: 2013-12-03

Last Posted Date: 2015-07-14

Lead Sponsor: QLT Inc.

Target Recruit Count: 43

Registration Number: NCT01999764

Locations: 🇺🇸
Sall Research Medical Center, Artesia, California, United States
🇺🇸
California Retina Consultants, Santa Barbara, California, United States
🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States

and more 4 locations

Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)

Phase 1

Completed

Conditions: Retinitis Pigmentosa (RP)

Interventions: Drug: QLT091001

First Posted Date: 2012-03-05

Last Posted Date: 2014-12-15

Lead Sponsor: QLT Inc.

Target Recruit Count: 5

Registration Number: NCT01543906

Locations: 🇨🇦
Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada
🇮🇪
Royal Victoria Eye and Ear Hospital, Dublin, Ireland

Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)

Phase 1

Completed

Conditions: RP (Retinitis Pigmentosa)
LCA (Leber Congenital Amaurosis)

First Posted Date: 2012-01-31

Last Posted Date: 2014-07-28

Lead Sponsor: QLT Inc.

Target Recruit Count: 27

Registration Number: NCT01521793

Locations: 🇺🇸
The Chicago Lighthouse (University of Illinois at Chicago, Pangere Center for Inherited Retinal Disease), Chicago, Illinois, United States
🇺🇸
Wilmer Eye Institute (Johns Hopkins University), Baltimore, Maryland, United States
🇨🇦
Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada

and more 3 locations

Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations

Phase 1

Completed

Conditions: LCA (Leber Congenital Amaurosis)
RP (Retinitis Pigmentosa)

First Posted Date: 2009-11-16

Last Posted Date: 2013-05-14

Lead Sponsor: QLT Inc.

Target Recruit Count: 32

Registration Number: NCT01014052

Locations: 🇺🇸
The Chicago Lighthouse for People Who Are Blind or Visually Impaired (The Pangere Center For Inherited Retinal Diseases), Chicago, Illinois, United States
🇺🇸
Wilmer Eye Institute (Johns Hopkins University), Baltimore, Maryland, United States
🇺🇸
Scheie Eye Institute, Philadelphia, Pennsylvania, United States

and more 4 locations

Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Human Volunteers

First Posted Date: 2008-10-03

Last Posted Date: 2009-03-30

Lead Sponsor: QLT Inc.

Target Recruit Count: 18

Registration Number: NCT00765427

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)

Phase 2

Completed

Conditions: Choroidal Neovascularization
Macular Degeneration

Interventions: Drug: verteporfin
Drug: ranibizumab
Drug: dexamethasone

First Posted Date: 2007-06-27

Last Posted Date: 2011-06-02

Lead Sponsor: QLT Inc.

Target Recruit Count: 162

Registration Number: NCT00492284

Locations: 🇺🇸
Retina Centers, PC, Tucson, Arizona, United States

A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

Phase 2

Terminated

Conditions: End Stage Renal Disease

First Posted Date: 2006-09-28

Last Posted Date: 2011-04-04

Lead Sponsor: QLT Inc.

Target Recruit Count: 3

Registration Number: NCT00381602

Locations: 🇺🇸
Tulane University Medical School, New Orleans, Louisiana, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Visudyne® in Occult (VIO)

Phase 3

Completed

Conditions: Macular Degeneration

First Posted Date: 2005-07-21

Last Posted Date: 2005-07-21

Lead Sponsor: QLT Inc.

Target Recruit Count: 364

Registration Number: NCT00121407

Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

Phase 2

Terminated

Conditions: Prostatic Hyperplasia

First Posted Date: 2005-06-30

Last Posted Date: 2006-10-03

Lead Sponsor: QLT Inc.

Target Recruit Count: 180

Registration Number: NCT00116571

Locations: 🇺🇸
San Bernardino Urological Associates, San Bernardino, California, United States
🇺🇸
Regional Urology, LLC, Shreveport, Louisiana, United States
🇺🇸
Drs Werner, Murdock & Francis PA Urology Associates, Greenbelt, Maryland, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy